Recent development of targeted approaches for the treatment of breast cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent development of targeted approaches for the treatment of breast cancer
Authors
Keywords
Breast cancer, Estrogen receptor, Hedgehog/Gli 1 signaling, Immunomodulators, Angiogenesis, Growth factor receptor inhibitors
Journal
Breast Cancer
Volume 24, Issue 2, Pages 191-219
Publisher
Springer Nature
Online
2016-10-31
DOI
10.1007/s12282-016-0732-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RAD1901
- (2015) Fiona Garner et al. ANTI-CANCER DRUGS
- Subglutinol A, an immunosuppressive α-pyrone diterpenoid from Fusarium subglutinans, acts as an estrogen receptor antagonist
- (2015) Wonchung Lim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- New approaches for improving outcomes in breast cancer in Europe
- (2015) Angelo Di Leo et al. BREAST
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- (2015) Gayathri Nagaraj et al. BREAST CANCER RESEARCH AND TREATMENT
- Notch signaling: An emerging therapeutic target for cancer treatment
- (2015) Xun Yuan et al. CANCER LETTERS
- Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
- (2015) Janice Lu Journal of Hematology & Oncology
- Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
- (2015) Sébastien L. Degorce et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
- (2015) Andiliy Lai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
- (2015) Donald P. McDonnell et al. JOURNAL OF MEDICINAL CHEMISTRY
- EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan
- (2015) Jian Guan et al. MEDICAL ONCOLOGY
- Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
- (2015) Anita Kort et al. PHARMACEUTICAL RESEARCH
- Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action
- (2015) Yaghoub Safdari et al. PHARMACOLOGICAL RESEARCH
- The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
- (2015) David Berman et al. PHARMACOLOGY & THERAPEUTICS
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- (2015) R. Elancheran et al. MedChemComm
- Genistein induces apoptosis by the inactivation of the IGF-1R/p-Akt signaling pathway in MCF-7 human breast cancer cells
- (2015) Jun Chen et al. Food & Function
- Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
- (2015) Annelies Gonnissen et al. Oncotarget
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
- (2014) Robert Coleman et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
- (2014) Sylvia M. Lee et al. CANCER
- Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
- (2014) Leanne Stalker et al. Cancer Cell International
- First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
- (2014) Parvin F. Peddi et al. Therapeutic Advances in Medical Oncology
- Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials
- (2013) André F. Carvalho et al. CANCER TREATMENT REVIEWS
- Overexpression of Gli1 in cancer interstitial tissues predicts early relapse after radical operation of breast cancer
- (2013) Ying-Hua Li et al. Chinese Journal of Cancer Research
- Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer
- (2013) Thehang Luu et al. Clinical Breast Cancer
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer
- (2013) Lorelei A. Mucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
- (2013) Tina Sharma et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines – Lessons for design of combination targeted therapy
- (2012) Brian J. Park et al. CANCER LETTERS
- P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.
- (2012) PD Ryan et al. CANCER RESEARCH
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
- (2012) D. H. Fagan et al. CANCER RESEARCH
- Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
- (2012) B. Ramaswamy et al. CANCER RESEARCH
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
- (2011) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
- (2011) Aman Buzdar et al. CANCER
- Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
- (2011) J. Gao et al. CANCER RESEARCH
- Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines
- (2011) Yeon-Jin Kwon et al. CLINICAL & EXPERIMENTAL METASTASIS
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer
- (2010) Masae Souzaki et al. CANCER SCIENCE
- Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
- (2010) J. Baselga et al. CLINICAL CANCER RESEARCH
- Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions
- (2010) Y.R. Santosh Laxmi et al. INTERNATIONAL JOURNAL OF CANCER
- Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study
- (2010) Tobias Bäuerle et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen
- (2010) Naomi Suzuki et al. INTERNATIONAL JOURNAL OF CANCER
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Notch Signaling Pathway as a Therapeutic Target in Breast Cancer
- (2010) H. Al-Hussaini et al. MOLECULAR CANCER THERAPEUTICS
- Antiovulatory effect of a single injection of pure antiestrogen ZK 191703 at early stage of rat estrus cycle
- (2009) Tsuyuki Nishino et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
- (2009) D Sachdev et al. ONCOGENE
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now